AgingResearch.NewsJoin free
NPJ Dementia

Toward personalized medicine in AD/ADRD through genetic-exposome dementia risk assessments

By Paulina Tolosa-Tort, Meri Okorie, Aadrita Chatterjee, Show 2 more authorsShea J. Andrews
Fig. 1. GEDRA enables risk stratification before biomarker and clinical changes in midlife.
Open the figure at full size
Fig. 1. GEDRA enables risk stratification before biomarker and clinical changes in midlife.GEDRA enables risk stratification before biomarker and clinical changes in midlife.Tolosa-Tort et al.
ReviewBiomarkers
Paper
Follow

Abstract

Genetic-Exposome Dementia Risk Assessments (GEDRA) integrate genomic and environmental risk factors into actionable, patient-centered tools for Alzheimer's disease and related dementias (AD/ADRD). By enabling midlife risk stratification before biomarker or cognitive changes, GEDRA supports personalized medicine through targeted screening, tailored interventions, treatment guidance, and proactive planning. Strategic investment in GEDRA will advance responsible risk communication and translate precision prevention strategies into equitable, clinically meaningful practice.

More on Alzheimer's disease and related dementias